How much funding has Tortugas Neuroscience raised?

Tortugas Neuroscience has raised $106.0M in total funding, most recently a Series A round.

Who are Tortugas Neuroscience's investors?

Tortugas Neuroscience's investors include The Column Group, Cure Ventures, AN Venture Partners.

When was Tortugas Neuroscience founded?

Tortugas Neuroscience was founded in 2021.

Where is Tortugas Neuroscience headquartered?

Tortugas Neuroscience is headquartered in Framingham, Massachusetts, United States.

What industry is Tortugas Neuroscience in?

Tortugas Neuroscience operates in Biotech.

How many employees does Tortugas Neuroscience have?

Tortugas Neuroscience has 1-10 employees.

Tortugas Neuroscience

Framingham, United States · Founded 2021 · $106.0M raised

Biotech

Headquarters: Framingham, Massachusetts
Employees: 1–10
Founded: 2021
Business Model: B2B

Website: tortugasneuro.com
Total Funding: $106.0M
Last Round: $106.0M Series AApr 2026
Rounds: 1

About

Tortugas Neuroscience is a neurology-focused biotech company dedicated to developing novel medicines with derisked mechanisms of action for large, well-defined central nervous system indications. Launched in April 2026 with $106 million in Seed and Series A financing, the company is led by biotech veterans Jeff Jonas, M.D. (CEO) and Al Robichaud, Ph.D. (President, Head of R&D), both formerly of Sage Therapeutics. Its clinical-stage pipeline includes in-licensed programs from Eisai and Jiangsu Hansoh Pharmaceutical targeting schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies, with a strategic focus on once-daily oral formulations and clear regulatory pathways to approval.

Summary

Tortugas Neuroscience is a Biotech company based in Framingham, United States, founded in 2021. It has raised $106.0M in total across 1 round, most recently a $106.0M Series A round in Apr 2026. Investors include The Column Group, Cure Ventures and AN Venture Partners.